Monte Rosa Therapeutics (GLUE) Retained Earnings (2023 - 2025)
Historic Retained Earnings for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$431.1 million.
- Monte Rosa Therapeutics' Retained Earnings rose 462.92% to -$431.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.1 million, marking a year-over-year increase of 462.92%. This contributed to the annual value of -$438.6 million for FY2024, which is 1986.95% down from last year.
- Monte Rosa Therapeutics' Retained Earnings amounted to -$431.1 million in Q3 2025, which was up 462.92% from -$404.0 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Retained Earnings high stood at -$262.6 million for Q1 2023, and its period low was -$452.0 million during Q3 2024.
- Over the past 3 years, Monte Rosa Therapeutics' median Retained Earnings value was -$397.9 million (recorded in 2024), while the average stood at -$382.0 million.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Retained Earnings crashed by 5152.32% in 2024, and later soared by 565.16% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Retained Earnings stood at -$365.9 million in 2023, then decreased by 19.87% to -$438.6 million in 2024, then increased by 1.71% to -$431.1 million in 2025.
- Its Retained Earnings stands at -$431.1 million for Q3 2025, versus -$404.0 million for Q2 2025 and -$391.7 million for Q1 2025.